Abstract:The recognition of invading pathogens and endogenous molecules from damaged tissues by toll-like receptors (TLRs) triggers protective self-defense mechanisms. However, excessive TLR activation disrupts the immune homeostasis by sustained pro-inflammatory cytokines and chemokines production and consequently contributes to the development of many inflammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), infection-associated sepsis, atherosclerosis, and asthma. Therefore, inhibitors/antagonists targeting TLR signals may be beneficial to treat these disorders. In this article, we first briefly summarize the pathophysiological role of TLRs in the inflammatory diseases. We then focus on reviewing the current knowledge in both preclinical and clinical studies of various TLR antagonists/inhibitors for the prevention and treatment of inflammatory diseases. These compounds range from conventional small molecules to therapeutic biologics and nanodevices. In particular, nanodevices are emerging as a new class of potent TLR inhibitors for their unique properties in desired bio-distribution, sustained circulation, and preferred pharmacodynamic and pharmacokinetic profiles. More interestingly, the inhibitory activity of these nanodevices can be regulated through precise nano-functionalization, making them the next generation therapeutics or "nano-drugs." Although, significant efforts have been made in developing different kinds of new TLR inhibitors/antagonists, only limited numbers of them have undergone clinical trials, and none have been approved for clinical uses to date. Nevertheless, these findings and continuous studies of TLR inhibition highlight the pharmacological regulation of TLR signaling, especially on multiple TLR pathways, as future promising therapeutic strategy for various inflammatory and autoimmune diseases.

Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems

The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management

Toll‐like receptors in pathogenesis of neurodegenerative diseases and their therapeutic potential

Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders

Toll-like Receptors and Their Role in Neuropathic Pain and Migraine

TLR Signaling in Brain Immunity.

Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.

Toll-like receptors in inflammation, infection and cancer

Recent Trends in the Development of Toll-like Receptor 7/8-Targeting Therapeutics.

TLR9 and its signaling pathway in multiple sclerosis

Toll-like Receptors: Emerging Targets of Immunomodulation

Toll like receptor - potential drug targets in infectious disease.

TLR-Mediated Signal Transduction and Neurodegenerative Disorders

Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors

Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis

Toll-like Receptors as Versatile Regulators in the Nervous System

Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases

Toll-like receptor 4: A potential therapeutic target for multiple human diseases

Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity

From Molecular Mechanisms to Clinical Applications

Targeting Toll-Like Receptors With Small Molecule Agents